Based on the totality of scientific evidence available to FDA, it is reasonable to believe that LAGEVRIO may be effective for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death, as described in the Scope of Authorization (section II), and that, when used under the conditions described in this authorization, the known and potential benefits of LAGEVRIO outweigh the known and potential risks of such product.
Adaptado de: https://www.fda.gov/media/155053/download Acessado em 21 de abril de 2022.
The FDA in the US has authorized LAGEVRIO
